Taysha Gene Therapies, Inc.
TSHANext catalyst
TSHA-101
Infantile GM2 Gangliosidosis (Disorder)
Get an email about TSHA's next catalysts
Track Taysha Gene Therapies (TSHA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (data readout).See the timeline
2 upcoming, 1 past
TSHA-101 Phase 2 Est. Readout
Estimated primary completion for TSHA-101 trial (NCT04798235) in Infantile GM2 Gangliosidosis (Disorder). Topline data typically follows completion by weeks to months.
SourceData Readout — REVEAL
Taysha Gene Therapies outlined plans for a 6-month interim analysis of the REVEAL trial in H1 2027 with accompanying FDA feedback, while targeting completion of PPQ in Q4 2026.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TSHA-101 | Phase 2 | Infantile GM2 Gangliosidosis (Disorder) | - | - |
Frequently asked questions
What is in Taysha Gene Therapies, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Taysha Gene Therapies, Inc.'s (TSHA) pipeline across Phase 2. Its lead program is TSHA-101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Taysha Gene Therapies, Inc.'s next FDA catalyst?→
Taysha Gene Therapies, Inc.'s (TSHA) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TSHA biotech catalysts?→
Add TSHA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Taysha Gene Therapies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.